Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

NCT01843062 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

233

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated based on the findings of primary analysis at 18 months post-RAI treatment. Patients pending 3 year follow up had end of study phone call.

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Selumetinib
DRUG: Placebo
DRUG: Radioactive Iodine Therapy

Sponsor

AstraZeneca